CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
Authors
Allen J.
Bah-Sow O.Y.
+40 more
Bamber S.
Chinappa T.
Coleman D.J.
Davies G.R.
Diop H.
Dlamini C.N.
Dube T.
Fielding K.
Fourie B.
Gill L.
Gninafon M.
Hadebe T.
Kanyok T.
Levin J.
Lienhardt C.
Lienhardt C.
Master I.
Merle C.
Mitchison D.
Mitchison D.A.
Mkhize Z.
Mpangase P.
Mthiyane T.
Ngcobo C.P.
Odhiambo J.
Olowolagba A.
Osburne G.
Pala A.S.
Perronne C.
Pillay L.
Portaels F.
Ramjee A.
Reddy C.
Rustomjee R.
Rustomjee R.
Saul M.
Sirgel F.A.
Sturm A.W.
Suma K.F.
Tembe C.
Publication date
1 January 2008
Publisher
Abstract
SETTING: Current treatment for pulmonary tuberculosis (TB) might be shortened by the incorporation of fluoroquinolones (FQs). OBJECTIVES: A Phase II study aimed to assess the sterilising activities of three novel regimens containing FQs before a Phase III trial of a 4-month regimen containing gatifloxacin (GFX). DESIGN: A total of 217 newly diagnosed smear-positive patients were randomly allocated to one of four regimens: isoniazid (INH), pyrazinamide and rifampicin (RMP) with either ethambutol, GFX, moxifloxacin (MFX) or ofloxacin (OFX) for 2 months. At the end of the study, RMP and INH were given for 4 months. The rates of elimination of Mycobacterium tuberculosis were compared in the regimens using non-linear mixed effects modelling of the serial sputum colony counts (SSCC) during the first 8 weeks. RESULTS: After adjustment for covariates, MFX substitution appeared superior during the early phase of a biexponential fall in colony counts, but significant and similar acceleration of bacillary elimination during the late phase occurred with both GFX and MFX (P = 0.002). Substitution of OFX had no effect. These findings were supported by estimates of time to conversion, using Cox regression, but there were no significant differences in proportions culture-negative at 8 weeks. CONCLUSIONS: GFX and MFX improve the sterilising activity of regimens and might shorten treatment; their progression into Phase III trials therefore seems warranted. © 2008 The Union.Articl
Similar works
Full text
Available Versions
Stellenbosch University SUNScholar Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:scholar.sun.ac.za:10019.1/...
Last time updated on 27/05/2016